Trial Profile

Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-Naive HIV-Infected Subjects.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lopinavir/ritonavir (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacogenomic

Most Recent Events

19 Apr 2018 Results published in the AIDS
06 Mar 2013 Results of the adipose tissue sub-study presented at the 20th Conference on Retroviruses and Opportunistic Infections.
21 Feb 2013 Planned end date changed from 1 Mar 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com